A previous study showed that EGFR-activating mutations in NSCLC were associated with PARP1 inhibitor sensitivity30, but the detailed mechanisms by which TKIs activate PARP1 still need further investigation. This evidence concerns the gene PARP1 and non-small cell lung carcinoma.